Isosceles Pharmaceuticals

Executive Summary

Isosceles Pharmaceuticals is a San Diego-based preclinical-stage specialty pharmaceutical company focused on developing novel non-opioid, non-NSAID analgesics for acute pain management. The company leverages the body's endocannabinoid system by utilizing synthetic cannabidiol (CBD) delivered via parenteral routes, aiming to provide rapid-onset, long-acting pain relief. Founded in 2019, Isosceles addresses the critical need for safer, non-addictive alternatives to opioids, particularly in postoperative and acute care settings. Its platform targets a significant market opportunity within the opioid crisis, offering a potential breakthrough in pain management with reduced abuse liability. The company's preclinical programs are advancing toward IND-enabling studies, with a focus on demonstrating efficacy and safety in validated animal models. Isosceles' strategy includes building a robust intellectual property portfolio and seeking strategic partnerships to accelerate clinical development.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Analgesic Candidate70% success
• Q4 2026Publication of Preclinical Efficacy Data85% success
• Q3 2026Series A Funding or Strategic Partnership Announcement60% success